Login to Your Account


Other News To Note


Monday, January 23, 2012
• Carolus Therapeutics Inc., of San Diego, published preclinical data showing CT-2009 prevented lung damage in multiple mouse models of acute lung injury. The molecule is designed to disrupt heteromers formed by the chemokines CCL5 (RANTES) and CXCL4, interfering with recruitment of neutrophils and tissue damage.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription


»

BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Privacy Policy | Terms of Use
 
Part of Thompson Media Group LLC

Free Ezine

Sign up for Perspectives FREE e-mail newsletter.

Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.